Winterthur
Switzerland
lung cancer; neoadjuvant; chemotherapy; immunotherapy; durvalumab; stage IIIA
neoadjuvant, immune checkpoint inhibitor, surrogate, overall survival
surrogate, Overall survival, objective response rate, major pathological response, pathological complete response, relapse-free survival